If so, ACEIs and ARBs may have a beneficial effect on the course of COVID-19 by reducing ACE/AngII/AT1R signalling and thereby restoring the local balance between the activities of the ACE/AngII/AT1R and ACE2/Ang1–7/MasR axes (Fig. 3). The gene discussed is MAS1L; the disease is COVID-19.